ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.

The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.

First-in-human study starts include radioligands from Akiram and Philogen.

A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.

The French group takes a shot at Perspective with its second bet on Orano Med.

Meanwhile, Tecvayli stalls, but J&J still hopes for growth.